Nebenwirkungen · Leqembi
LEQEMBI 100 mg/mL concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 11
HOS-150425 · Präparat HOS-100312
Intracerebral Haemorrhage in the Indicated Population The incidence of intracerebral haemorrhage was 0.3% (1/286) of patients on lecanemab with a concomitant antithrombotic medication at the time of the event compared to 0.7% (3/450) of patients who did not. Patients taking lecanemab with an anticoagulant alone or combined with an antiplatelet medication or aspirin had an incidence of intracerebral haemorrhage of 1.5% (1/68 patients) compared to no patients on placebo.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-05T11:45:00Z · SHA-256 b5b97a1240d6c003d96cd8b3294bef8b3b5d33af33f6be54cfceee548b126f2d · Passage a32f35a4c09208982bd6b3b8e8787eb09c767f139e2f3c443f06692de827e667 · Zeichen 7902–8375 im Abschnitt